This site is intended for healthcare professionals
CDK 4/6 banner image
CDK4/6 inhibitors in breast cancer

Thank you

Read time: 5 mins
Last updated:22nd Aug 2023
Published:22nd Aug 2023

Thank you for completing the knowledge quiz and evaluation form! You will receive your CME accreditation certificate within 5 working days.

1. What is currently the only approved CDK4/6 inhibitor for treating early breast cancer?

The correct answer is B. Abemaciclib.

2. Approval of abemaciclib for use in people with high-risk HR+/HER2− early breast cancer was based on clinical trial data from which study?

The correct answer is D. monarchE.

3. What PARP inhibitor is recommended for people with early breast cancer, BRCA mutation and a high-risk of recurrence?

The correct answer is C. Olaparib.

Review the roundtable again